Cancer-Code Corporation Announces Licensing of Revolutionary Cancer Treatment Technology

PRLog (Press Release) - Apr. 29, 2012 - ALBUQUERQUE, NM - Cancer Code Corporation (C3) announces that it is the licensee of the cancer treatment approach covered in four pending patent applications based on inventor Eleanor Schuler’s neuro-code technology.  C3 currently has the exclusive rights in the United States and China for this cancer killing technology.  

The U.S. patent applications are as follows:

U.S. Patent Application Serial No. 12/334,212 entitled “Method to Switch-Off Cancer Cell Electrical Communication Codes as Medical Therapy”.

U.S. Patent Application Serial No. 12/936,778 entitled “System and Method to Elicit Apoptosis in Malignant Tumor Cells for Medical Therapy”.

U.S. Patent Application Serial No. 12/812,576 entitled “Method and System for Processing Cancer Cell Electrical Signals for Medical Therapy”

U.S. Patent Application Serial No. 12/936,791 entitled “Hybrid Scientific Computer System for Processing Cancer Cell Signals as Medical Therapy”

This cancer killing technology has the potential to replace current chemotherapy approaches, and represents the dawn of an entirely new treatment approach using tiny encoded signals to destroy cancer, quickly.  This new and exciting breakthrough is based on the fact that all cells communicate, including cancer cells.  This approach will “signal” the cancer cells to kill themselves.

About Cancer-Code Corporation

C3, located in Albuquerque, NM, is focusing on the development and testing of cancer treatment technology that takes advantage of the fact that all cells have an electrical process and adjacent cells communicate with one another.  The approach of C3 is geared toward this cancer cell communication and “wrecking" this cancer cell communication network through tiny pico-sparks defined as “Codes-of-Death” to disrupt this cancer cell communication network.  C3’s initial focus is the development of neuro-signaling communication to those malignant cancer cells to offer a unique treatment modality that is expected not to disturb normal adjacent structures and cells.  It is this neuro-signaling disrupting cancer cell communication that C3 intends to affect and cause cancer cell apoptosis rapidly.

Additional information about Cancer-Code Corporation can be found at http://www.cancercodecorp.com

Forward-Looking Statements

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.

Donald E. Nash, President
Cancer Code Corporation
117 Bryn Mawr Dr S.E.
Albuquerque, NM 87106
(505) 250-6574

E-mail: cancercode1@gmail.com